Cultural advice

The Australian National University acknowledges, celebrates and pays our respects to the Ngunnawal and Ngambri people of the Canberra region and to all First Nations Australians on whose traditional lands we meet and work, and whose cultures are among the oldest continuing cultures in human history.

Aboriginal and Torres Strait Islander peoples are advised that ANU Library collections may include images, names, voices, and other representations of deceased persons.

Material in the collection may contain terms, language or views that reflect the period in which the item was created and may be considered inappropriate today.

Immunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE database

dc.contributor.authorCortegiani, Andrea
dc.contributor.authorMadotto, Fabiana
dc.contributor.authorGregoretti, Cesare
dc.contributor.authorBellani, Giacomo
dc.contributor.authorLaffey, John
dc.contributor.authorPham, Tai
dc.contributor.authorVan Haren, Frank
dc.contributor.authorGiarratano, Antonino
dc.contributor.authorAntonelli, Massimo
dc.contributor.authorPesenti, Antonio
dc.date.accessioned2021-02-04T23:50:55Z
dc.date.available2021-02-04T23:50:55Z
dc.date.issued2018
dc.date.updated2020-11-02T04:26:15Z
dc.description.abstractBackground: The aim of this study was to describe data on epidemiology, ventilatory management, and outcome of acute respiratory distress syndrome (ARDS) in immunocompromised patients. Methods: We performed a post hoc analysis on the cohort of immunocompromised patients enrolled in the Large Observational Study to Understand the Global Impact of Severe Acute Respiratory Failure (LUNG SAFE) study. The LUNG SAFE study was an international, prospective study including hypoxemic patients in 459 ICUs from 50 countries across 5 continents. Results: Of 2813 patients with ARDS, 584 (20.8%) were immunocompromised, 38.9% of whom had an unspecified cause. Pneumonia, nonpulmonary sepsis, and noncardiogenic shock were their most common risk factors for ARDS. Hospital mortality was higher in immunocompromised than in immunocompetent patients (52.4% vs 36.2%; p < 0.0001), despite similar severity of ARDS. Decisions regarding limiting life-sustaining measures were significantly more frequent in immunocompromised patients (27.1% vs 18.6%; p < 0.0001). Use of noninvasive ventilation (NIV) as first-line treatment was higher in immunocompromised patients (20.9% vs 15.9%; p = 0.0048), and immunodeficiency remained independently associated with the use of NIV after adjustment for confounders. Forty-eight percent of the patients treated with NIV were intubated, and their mortality was not different from that of the patients invasively ventilated ab initio. Conclusions: Immunosuppression is frequent in patients with ARDS, and infections are the main risk factors for ARDS in these immunocompromised patients. Their management differs from that of immunocompetent patients, particularly the greater use of NIV as first-line ventilation strategy. Compared with immunocompetent subjects, they have higher mortality regardless of ARDS severity as well as a higher frequency of limitation of life-sustaining measures. Nonetheless, nearly half of these patients survive to hospital discharge.en_AU
dc.format.mimetypeapplication/pdfen_AU
dc.identifier.issn1364-8535en_AU
dc.identifier.urihttp://hdl.handle.net/1885/222046
dc.language.isoen_AUen_AU
dc.provenanceThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.en_AU
dc.publisherBioMed Centralen_AU
dc.rights© The Author(s). 2018en_AU
dc.rights.licenseCreative Commons Attribution 4.0 International Licenseen_AU
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en_AU
dc.sourceCritical Careen_AU
dc.subjectAcute respiratory failureen_AU
dc.subjectARDSen_AU
dc.subjectImmunocompromised patientsen_AU
dc.subjectMechanical ventilationen_AU
dc.subjectNoninvasive ventilationen_AU
dc.titleImmunocompromised patients with acute respiratory distress syndrome: secondary analysis of the LUNG SAFE databaseen_AU
dc.typeJournal articleen_AU
dcterms.accessRightsOpen Accessen_AU
local.bibliographicCitation.issue1en_AU
local.bibliographicCitation.startpage157en_AU
local.contributor.affiliationCortegiani, Andrea, University of Palermoen_AU
local.contributor.affiliationMadotto, Fabiana, University of Milano-Bicoccaen_AU
local.contributor.affiliationGregoretti, Cesare, University of Palermoen_AU
local.contributor.affiliationBellani, Giacomo, University of Milan-Bicoccaen_AU
local.contributor.affiliationLaffey, John, University of Torontoen_AU
local.contributor.affiliationPham, Tai, St Michael's Hospital, University of Torontoen_AU
local.contributor.affiliationVan Haren, Frank, College of Health and Medicine, ANUen_AU
local.contributor.affiliationGiarratano, Antonino, University of Palermoen_AU
local.contributor.affiliationAntonelli, Massimo, Fondazione Policlinico Universitario A. Gemellien_AU
local.contributor.affiliationPesenti, Antonio, University of Milanen_AU
local.contributor.authoruidVan Haren, Frank, u5325459en_AU
local.description.notesImported from ARIESen_AU
local.identifier.absfor110310 - Intensive Careen_AU
local.identifier.absseo920115 - Respiratory System and Diseases (incl. Asthma)en_AU
local.identifier.absseo920108 - Immune System and Allergyen_AU
local.identifier.ariespublicationu5786633xPUB283en_AU
local.identifier.citationvolume22en_AU
local.identifier.doi10.1186/s13054-018-2079-9en_AU
local.identifier.scopusID2-s2.0-85048497595
local.publisher.urlhttp://ccforum.com/en_AU
local.type.statusPublished Versionen_AU

Downloads

Original bundle

Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
01_Cortegiani_Immunocompromised_patients_2018.pdf
Size:
789.21 KB
Format:
Adobe Portable Document Format
abcd